EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Will Vietnamese American communities benefit from new Alzheimer's disease treatments?

Kim Hoang, Oanh L. Meyer, Joshua D. Grill

Alzheimer's & Dementia: Behavior & Socioeconomics of Aging · 2025

DOI: 10.1002/bsa3.70009 ↗
AbstractBibliografische Angaben

Abstract

Abstract Novel anti‐amyloid beta (Aβ) immunotherapies for Alzheimer's disease (AD) have achieved regulatory approval and offer promising results for patients with mild cognitive impairment (MCI) and mild dementia. Given the importance of early intervention, uncertainties arise for populations, such as Vietnamese Americans, who are challenged by systemic barriers and cultural health beliefs that may hinder access to timely diagnoses. While clinical trials have demonstrated significant slowing in functional and cognitive decline in patients with MCI and mild AD dementia, the safety and efficacy of these treatments remain unclear for Vietnamese American individuals and other groups who were underrepresented in the trials that supported approval. As such, this population may be at risk of not benefiting to the same extent as their White and even other Asian American counterparts. Future research is warranted to improve equitable access to these novel AD treatments. Highlights FDA‐approved anti‐Aβ immunotherapies reduced cognitive and functional decline in patients with MCI and mild dementia in clinical trials. Several minority populations, including Vietnamese American communities, were underrepresented in these trials. Systemic and cultural barriers within the Vietnamese community may hinder access to timely care, an essential component to the efficacy of anti‐Aβ immunotherapies. Additional research on the cultural perspectives and health behaviors of Vietnamese American patients and their providers will be necessary to ensure equitable access to novel AD treatments.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →